Survival from breast cancer in england and wales up to 2001

British Journal of Cancer

Volumn 99, Issue , 2008, Pages S56-S58

  Leary, A ^a   Smith, I E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; FLUOROURACIL; LETROZOLE; METHOTREXATE; PLACEBO; TAMOXIFEN; TAMOXIFEN CITRATE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AWARENESS; BREAST CANCER; BREAST METASTASIS; BREAST SELF EXAMINATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; EDUCATION; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; MAMMOGRAPHY; MASTECTOMY; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SURVIVAL RATE; UNITED KINGDOM;

AGED; AWARENESS; BREAST NEOPLASMS; CARCINOMA; ENGLAND; FEMALE; FORECASTING; HUMANS; MASS SCREENING; MIDDLE AGED; NEOPLASM METASTASIS; SOCIAL CLASS; SURVIVAL ANALYSIS; WALES;

EID: 52449106132     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604588     Document Type: Article

References (25)

1. Baum M (2004) Commentary: false premises, false promises and false positives–the case against mammographic screening for breast cancer. Int J Epidemiol 33: 66–67; discussion 69–73
2. Chia SK, Speers CH, D’yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O’Reilly SE, Olivotto IA (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110: 973–979
3. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y, Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366: 2087–2106
4. Dinh P, de Azambuja E, Piccart-Gebhart MJ (2007) Trastuzumab for early breast cancer: current status and future directions. Clin Adv Hematol Oncol 5: 707–717
5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28 896 women. N Engl J Med 319: 1681–1692
6. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (1998a) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451–1467
7. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (1998b) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930–942
8. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717
9. Erbas B, Provenzano E, Armes J, Gertig D (2006) The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat 97: 135–144
10. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R (2000) Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 160: 953–958
11. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97: 1262–1271
12. Gotzsche PC (2004) On the benefits and harms of screening for breast cancer. Int J Epidemiol 33: 56–64; discussion 69–73
13. Kelsey JL, Fischer DB, Holford TR, LiVoisi VA, Mostow ED, Goldenberg IS, White C (1981) Exogenous estrogens and other factors in the epidemiology of breast cancer. J Natl Cancer Inst 67: 327–333
14. Kingsmore D, Hole D, Gillis C (2004) Why does specialist treatment of breast cancer improve survival? The role of surgical management. Br J Cancer 90: 1920–1925
15. Kosters JP, Gotzsche PC (2003) Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst Rev 2: CD003373
16. Lin NU, Winer EP (2008) Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 26: 798–805
17. McCready T, Littlewood D, Jenkinson J (2005) Breast self-examination and breast awareness: a literature review. J Clin Nurs 14: 570–578
18. Moss SM, Michel M, Patnick J, Johns L, Blanks R, Chamberlain J (1995) Results from the NHS breast screening programme 1990–1993. J Med Screen 2: 186–190
19. Nolvadex Adjuvant Trial Organisation (NATO) (1985) Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation. Lancet 1: 836–840
20. Olsen O, Gotzsche PC (2001) Cochrane review on screening for breast cancer with mammography. Lancet 358: 1340–1342
21. Quinn MJ, Cooper N, Rachet B, Mitry E, Coleman MP (2008) Survival from cancer of the breast in women in england and wales up to 2001. Br J Cancer 99(Suppl 1): S53–S55
22. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673–1684
23. Smith IE (2002) New drugs for breast cancer. Lancet 360: 790–792
24. Taylor A, Cheng KK (2003) Social deprivation and breast cancer. J Public Health Med 25: 228–233
25. Welch HG, Black WC (1997) Using autopsy series to estimate the disease ‘reservoir’ for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 127: 1023–1028